NGR016: Randomized Phase II Study Evaluating Two Doses of NGR-hTNF Administered Either as Single Agent or in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma (STS)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs NGR-TNF (Primary) ; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Sponsors MolMed
- 12 Jun 2016 Status is completed in Italy (End date: 2016-05-09) as per European Clinical Trials Database record.
- 05 Apr 2015 Planned End Date changed from 1 Dec 2013 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
- 05 Apr 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History